notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title 炎症性腸疾患の新規治療薬と将来展望
Subtitle 今月のテーマ (総論) : 炎症性腸疾患におけるTreat to Targetのエビデンス
Authors 猿田雅之1)
Authors (kana)
Organization 1)東京慈恵会医科大学内科学講座消化器・肝臓内科
Journal 日本消化器病学会雑誌
Volume 118
Number 3
Page 193-202
Year/Month 2021 / 3
Article 報告
Publisher 日本消化器病学会
Abstract 要旨: 潰瘍性大腸炎とクローン病に代表される炎症性腸疾患(IBD)は増加の一途を辿り, いまだ完治させることはできないが, 有効な治療薬の開発は進んでいる. 近年のIBD治療の大きな転機は抗TNF-α抗体の登場で, 高い寛解率と維持率から治療史を変える薬剤となった. 以降, サイトカインを標的とした抗体療法の開発が続いているが, 一方で抗薬物抗体の出現による二次無効の問題も懸念されている. 現在, 慢性炎症の制御を目的としたリンパ球の遊走や侵入を抑える薬剤や, 炎症性サイトカインの結合後に誘導される細胞内シグナルを標的とした薬剤も登場している. 本稿では, 新規に展開するIBD治療薬の現状を示し, 治療の将来展望についても概説する.
Practice 臨床医学：内科系
Keywords 炎症性腸疾患, サイトカイン, 生物学的製剤, インテグリン, 経口低分子化合物
  • 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
download全文ダウンロード(10.29MB)

参考文献

  • 1) Murakami Y, Nishiwaki Y, Oba MS, et al: Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol 54;1070-1077:2019
  • 2) Targan SR, Hanauer SB, van Deventer SJ, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337;1029-1035:1997
  • 3) van Schouwenburg PA, Rispens T, Wolbink GJ: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9;164-172:2013
  • 4) Sands BE: Therapy of inflammatory bowel disease. Gastroenterology 118 (suppl 1);S68-S82:2000
  • 5) Weisshof R, El Jurdi K, Zmeter N, et al: Emerging therapies for inflammatory bowel disease. Adv Ther 35;1746-1762:2018
残りの50件を表示する
  • 6) Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3;133-146:2003
  • 7) Monteleone G, Biancone L, Marasco R, et al: Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112;1169-1178:1997
  • 8) Neurath MF, Fuss I, Kelsall BL, et al: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182;1281-1290:1995
  • 9) Oppmann B, Lesley R, Blom B, et al: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13;715-725:2000
  • 10) Parham C, Chirica M, Timans J, et al: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168;5699-5708:2002
  • 11) Morishima N, Mizoguchi I, Takeda K, et al: TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem Biophys Res Commun 386;105-110:2009
  • 12) Behzadi P, Behzadi E, Ranjbar R: IL-12 family cytokines: general characteristics, pathogenic microorganisms, receptors, and signaling pathways. Acta Microbiol Immunol Hung 63;1-25:2016
  • 13) Korn T, Bettelli E, Oukka M, et al: IL-17 and Th17 Cells. Annu Rev Immunol 27;485-517:2009
  • 14) Duerr RH, Taylor KD, Brant SR, et al: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314;1461-1463:2006
  • 15) Feagan BG, Sandborn WJ, Gasink C, et al: Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375;1946-1960:2016
  • 16) Sands BE, Sandborn WJ, Panaccione R, et al: Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381;1201-1214:2019
  • 17) Feagan BG, Sandborn WJ, D'Haens G, et al: Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389;1699-1709:2017
  • 18) Feagan BG, Panes J, Ferrante M, et al: Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol 3;671-680:2018
  • 19) Sands BE, Chen J, Feagan BG, et al: Efficacy and safety of MEDI2070. an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: A phase 2a study. Gastroenterology 153;77-86:2017
  • 20) Sandborn WJ, Ferrante M, Bhandari BR, et al: Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 158;537-549:2020
  • 21) Sandborn WJ, Ferrante M, Bhandari BR, et al: Efficacy and safety of continued treatment with Mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol S1542-3565(20)31289-1:2020
  • 22) Blauvelt A, Papp KA, Griffiths CEM, et al: Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76;405-417:2017
  • 23) Mavers M, Ruderman EM, Perlman H: Intracellular signal pathways: potential for therapies. Curr Rheumatol Rep 11;378-385:2009
  • 24) Ghoreschi K, Laurence A, O'Shea JJ: Janus kinases in immune cell signaling. Immunol Rev 228;273-287:2009
  • 25) Danese S, Grisham M, Hodge J, et al: JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 310;G155-G162:2016
  • 26) Sandborn WJ, Ghosh S, Panes J, et al: Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367;616-624:2012
  • 27) Sandborn WJ, Su C, Sands BE, et al: Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376;1723-1736:2017
  • 28) Vermeire S, Schreiber S, Petryka R, et al: Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389;266-275:2017
  • 29) Sandborn WJ, Feagan BG, Loftus EV Jr, et al: Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology 158;2123-2138.e8:2020
  • 30) Sandborn WJ, Ghosh S, Panes J, et al: Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 158;2139-2149.e14:2020
  • 31) Papp K, Gordon K, Thaci D, et al: Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med 379;1313-1321:2018
  • 32) Saruta M, Papadakis KA: Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am 43;581-601:2014
  • 33) Saida T, Kira JI, Kishida S, et al: Natalizumab Trial Principal Investigators. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord 11;25-31:2017
  • 34) Saida T, Kira JI, Kishida S, et al: Natalizumab Trial Principal Investigators. Safety and efficacy of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis: open-label extension study of a phase 2 trial. Neurol Ther 6;39-55:2017
  • 35) Sandborn WJ, Colombel JF, Enns R, et al: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353;1912-1925:2005
  • 36) Feagan BG, Sandborn WJ, Hass S, et al: Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroentorol 102;2737-2746:2007
  • 37) Van Assche G, Van Ranst M, Sciot R, et al: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353;362-368:2005
  • 38) Feagan BG, Rutgeerts P, Sands BE, et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369;699-710:2013
  • 39) Sandborn WJ, Feagan BG, Rutgeerts P, et al: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369;711-721:2013
  • 40) Vermeire S, Loftus EV Jr, Colombel JF, et al: Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis 11;412-424:2017
  • 41) Sandborn WJ, Baert F, Danese S, et al: Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 158;562-572.e12:2020
  • 42) Yoshimura N, Watanabe M, Motoya S, et al: Safety and Efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. AJM300 Study Group. Gastroenterology 149;1775-1783.e2:2015
  • 43) Sandborn WJ, Lee SD, Tarabar D, et al: Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut 67;1824-1835:2018
  • 44) Vermeire S, Sandborn WJ, Danese S, et al: Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 390;135-144:2017
  • 45) Takuwa Y, Takuwa N, Sugimoto N: The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem 131;767-771:2002
  • 46) Spiegel S, Milstien S: The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 11;403-415:2011
  • 47) Sandborn WJ, Feagan BG, Wolf DC, et al: Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374;1754-1762:2016
  • 48) Sandborn W, D'Haens GR, Wolf DC, et al: Ozanimod as induction therapy in moderate-to-severe ulcerative colitis: Results from the phase 3, randomized, double-blind, placebo-controlled True North study. Paper presented in late-breaking oral presentation (#LB2) at United European Gastroenterology (UEG) Week Virtual 2020;October 11-13, 2020
  • 49) Danese S, Feagan BG, Wolf DC, et al: Ozanimod as maintenance therapy in patients with moderate-to-severe ulcerative colitis: Results from the phase 3, randomized, double-blind, placebo-controlled True North study. Paper presented in late-breaking oral presentation (#LB10) at United European Gastroenterology (UEG) Week Virtual 2020;October 11-13, 2020
  • 50) Feagan BG, Sandborn WJ, Danese S, et al: Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 5;819-828:2020
  • 51) Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al: Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology 158;550-561:2020
  • 52) Valatas V, Kolios G, Bamias G: TL1A (TNFSF15) and DR3 (TNFRSF25): A co-stimulatory system of cytokines with diverse functions in gut mucosal immunity. Front Immunol 10;583:2019
    pubmed
  • 53) Danese S, Klopocka M, Scherl EJ, et al: Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study. Paper presented at 15th Congress of the European Crohn's and Colitis Organisation (ECCO): February 12-15, Vienna, Austria, 2020
  • 54) Spadaccini M, D'Alessio S, Peyrin-Biroulet L, et al: PDE4 inhibition and inflammatory bowel disease: A novel therapeutic avenue. Int J Mol Sci 18;1276:2017
  • 55) Danese S, Neurath MF, Kopon A, et al: Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin Gastroenterol Hepatol 18;2526-2534.e9:2020
はじめての方へ
個人／法人会員登録のご案内